MorphoSys to Present at Six Upcoming Investor Conferences
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announcedtoday that its management will give company presentations at severalupcoming investor conferences.Sal. Oppenheim European Healthcare Investors ConferenceDate: Monday, August 31, 2009Time: 04:10 pm CET (03:10 pm BST, 10:10 am EDT)Venue: Frankfurt/Main, GermanyPresenter: Dr. Simon Moroney, CEO of MorphoSys AGRodman & Renshaw Annual Global Investment ConferenceDate: Thursday, September 10, 2009Time: 10:25 am EDT (04:25 pm CET, 03:25 pm BST)Venue: New York, USAPresenter: Dr. Simon Moroney, CEO of MorphoSys AGGerman Healthcare ConferenceOrganizer: DZ Bank with Deutsche Börse GroupDate: Friday, September 11, 2009Time: 10:45 am CET (04:45 am EDT, 09:45 am BST)Venue: Zurich, SwitzerlandPresenter: Mr. Dave Lemus, CFO of MorphoSys AGBank of America Merrill Lynch Global Healthcare ConferenceDate: Wednesday, September 16, 2009Time: 11:20 am BST (12:20 pm CET, 06:20 am EDT)Venue: London, UKPresenter: Dr. Simon Moroney, CEO of MorphoSys AGUBS Global Life Sciences ConferenceDate: Monday, September 21, 2009Time: 02:30 pm EDT (08:30 pm CET, 07:30 pm BST)Venue: New York, USAPresenter: Dr. Simon Moroney, CEO of MorphoSys AGCommerzbank Life Sciences ForumDate: Thursday, October 1, 2009Venue: Frankfurt/Main, GermanyPresenter: Dr. Simon Moroney, CEO of MorphoSys AGThe PDF versions and, if available, live and archived webcasts of thepresentations will be provided at www.morphosys.com.About MorphoSys:MorphoSys is an independent biotechnology company that develops novelantibodies for therapeutic, diagnostic and research applications. TheCompany's HuCAL technology is one of the most powerful methodsavailable for generating fully human antibodies. By successfullyapplying this and other proprietary technologies, MorphoSys hasbecome a leader in the field of therapeutic antibodies, one of thefastest-growing drug classes in human health-care. Through itsalliances with some of the world's leading pharmaceutical companies,MorphoSys has created a pipeline of more than 60 drug candidates. TheCompany is expanding its drug pipeline by adding new partneredprograms, and by building a portfolio of fully-owned therapeuticantibodies. For its proprietary portfolio, the Company is focused onthe areas of oncology and inflammation, within which it plans to haveeight active programs by the end of 2009. Its most advanced programis MOR103, a first-in-class, fully human antibody against GM-CSF.MorphoSys expects to commence a Phase Ib/IIa trial of this antibodyin rheumatoid arthritis patients in the second half of 2009. Via itsbusiness unit AbD Serotec, MorphoSys is expanding the reach of itstechnologies in the diagnostics and research markets. MorphoSys isheadquartered in Munich, Germany and listed on the Frankfurt StockExchange under the symbol "MOR". For further information, visithttp://www.morphosys.com/HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registeredtrademarks of MorphoSys AGThis communication contains certain forward-looking statementsconcerning the MorphoSys group of companies. The forward-lookingstatements contained herein represent the judgment of MorphoSys as ofthe date of this release and involve risks and uncertainties. Shouldactual conditions differ from the Company's assumptions, actualresults and actions may differ from those anticipated. MorphoSys doesnot intend to update any of these forward-looking statements as faras the wording of the relevant press release is concerned.For more information, please contact MorphoSys:Dr. Claudia Gutjahr-LöserHead of Corporate Communications & IRTel: +49 (0) 89 / 899 27-122gutjahr-loeser(at)morphosys.comMario BrkuljSenior Manager Corporate Communications & IRTel: +49 (0) 89 / 899 27-454brkulj(at)morphosys.comJessica KulpiSpecialist Corporate Communications & IRTel: +49 (0) 89 / 899 27-454kulpi(at)morphosys.comhttp://hugin.info/130295/R/1337859/318974.pdf --- End of Message ---MorphoSys AGLena-Christ-Str. 48 Martinsried / München GermanyWKN: 663200; ISIN: DE0006632003; Index: CDAX, HDAX, Prime All Share, TECH All Share, TecDAX, MIDCAP;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 28.08.2009 - 14:00 Uhr
Sprache: Deutsch
News-ID 5240
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 313 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Present at Six Upcoming Investor Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
